Replies to post #190895 on Biotech Values

[biomaven0]

>>ALXN acquires GEVA for $226/sh* in cash and stock

However much the bears scream about biotech being a bubble, as long as the sector gets support from buyouts like this, it will continue strong.

We still haven't seen any moves by GILD - their billions must be burning a hole in their very deep pockets.

Maybe we should have a contest to see who GILD will buy (it's going to be more than one company I suspect).

Peter

[biocqr]

Alexion will acquire Synageva for consideration of $115 in cash

The last 13-F the Bakers owned 10.6M shares of GEVA...that's $1.2B of new powder.

[DewDiligence]

ALXN—FDA delays review of Kanuma (sebelipase alfa) by three months due to CMC issues (new PDUFA is 12/8/15):

http://finance.yahoo.com/news/alexion-receives-notification-pdufa-date-110000590.html

ALXN acquired Kanuma in the controversial GEVA buyout (#msg-113395760).

[DewDiligence]

FDA approves ALXN’s Kanuma for LAL deficiency:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476013.htm

The approval entitles ALXN to an FDA priority-review voucher.

ALXN picked up Kanuma in the controversial $8.4B GEVA buyout in May 2015 (#msg-113395760).

[DewDiligence]

ALXN misses primary endpoint in phase-3 MG trial:

http://finance.yahoo.com/news/alexion-announces-topline-results-phase-200100096.html

…the primary efficacy endpoint of change from baseline in Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, a patient-reported assessment, at week 26, did not reach statistical significance (p=0.0698) as measured by a worst-rank analysis.

CC at 5pm ET.